Zacks Investment Research downgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a buy rating to a hold rating in a report released on Tuesday, January 9th.
According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
Other analysts have also recently issued research reports about the stock. HC Wainwright reiterated a buy rating and issued a $40.00 price objective on shares of ProQR Therapeutics in a research note on Tuesday, September 26th. ValuEngine upgraded shares of ProQR Therapeutics from a sell rating to a hold rating in a research report on Friday, September 15th. Chardan Capital restated a neutral rating on shares of ProQR Therapeutics in a research report on Sunday, September 17th. JMP Securities lifted their target price on shares of ProQR Therapeutics from $14.00 to $20.00 and gave the stock an outperform rating in a research report on Tuesday, September 26th. Finally, Leerink Swann restated an outperform rating and set a $12.00 target price (up previously from $10.00) on shares of ProQR Therapeutics in a research report on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $18.88.
ProQR Therapeutics (NASDAQ:PRQR) opened at $3.17 on Tuesday. ProQR Therapeutics has a 52-week low of $2.75 and a 52-week high of $6.90. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.72 and a current ratio of 6.72. The stock has a market cap of $101.95 and a price-to-earnings ratio of -1.67.
ProQR Therapeutics (NASDAQ:PRQR) last issued its earnings results on Monday, November 20th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. equities analysts anticipate that ProQR Therapeutics will post -2.06 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nine Chapters Capital Management LLC purchased a new position in shares of ProQR Therapeutics in the third quarter valued at $133,000. Wells Fargo & Company MN raised its holdings in ProQR Therapeutics by 212.6% in the third quarter. Wells Fargo & Company MN now owns 43,226 shares of the biopharmaceutical company’s stock valued at $210,000 after acquiring an additional 29,400 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in ProQR Therapeutics in the second quarter valued at $2,028,000. Artal Group S.A. raised its holdings in ProQR Therapeutics by 25.0% in the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Sphera Funds Management LTD. raised its holdings in ProQR Therapeutics by 60.6% in the third quarter. Sphera Funds Management LTD. now owns 530,000 shares of the biopharmaceutical company’s stock valued at $2,571,000 after acquiring an additional 200,000 shares in the last quarter. Institutional investors own 31.63% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “ProQR Therapeutics (NASDAQ:PRQR) Lowered to Hold at Zacks Investment Research” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/03/zacks-investment-research-downgrades-proqr-therapeutics-prqr-to-hold.html.
About ProQR Therapeutics
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.
Get a free copy of the Zacks research report on ProQR Therapeutics (PRQR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.